← Back to Search

Behavioural Intervention

Active Vibrotactile Coordinated Reset (vCR) for Overactive Bladder

N/A
Waitlist Available
Led By Peter Tass, MD PhD
Research Sponsored by Synergic Medical Technologies, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14months

Summary

This trial is testing a special glove that sends gentle vibrations to the fingertips to help Parkinson's disease patients. The goal is to offer a non-invasive alternative to medications and surgeries, which can have severe side effects or risks. The vibrations are believed to help the brain better control movement, potentially reducing symptoms. A wearable tremor suppression glove has been previously demonstrated to manage hand and finger tremor in Parkinson's disease patients.

Eligible Conditions
  • Overactive Bladder
  • Parkinson's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 14months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Movement Disorders Society Unified Parkinson's Disease Rating Scale Part 3
Secondary study objectives
Gait
Kinesia One motor evaluation
Levodopa equivalent daily dose (LEDD)
+8 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Active Vibrotactile Coordinated Reset (vCR)Active Control1 Intervention
Participants in this arm will receive active vCR stimulation.
Group II: Sham Vibrotactile Coordinated Reset (vCR)Placebo Group1 Intervention
Participants in this arm will receive sham vCR stimulation.

Find a Location

Who is running the clinical trial?

Stanford UniversityOTHER
2,471 Previous Clinical Trials
17,501,742 Total Patients Enrolled
Synergic Medical Technologies, Inc.Lead Sponsor
2 Previous Clinical Trials
60 Total Patients Enrolled
Peter Tass, MD PhDPrincipal InvestigatorStanford University
~9 spots leftby Nov 2025